Kornimate/medical-research-clean huggingface dataset:
what makes people better at retrieving difficult words?

Conditions: Healthy Aging

Summary: this study is being conducted to learn more about how various personal and situational characteristics are related to the ability to produce words in response to definitions. participants will watch a video, then see definitions and try to come up with a word that fits each one. participants will also complete some surveys and other measures. collected data will give researchers a better understanding of how individuals' personality and cognitive traits and setting in which word retrieval occurs relate to the ability to produce individual words.

this study is being conducted to learn more about how various personal and situational characteristics are related to the ability to produce words in response to definitions. adult participants ages 18-30 and 65-80 will participate in videoconference calls during which a video is shown and definitions are presented. participants will try to come up with a word that fits each definition, and then complete some surveys, including some about anxiety, mindfulness, attention, vocabulary, and demographics. participation will take approximately 1.25 hours. collected data will be de-identified, and the aggregate data will give researchers a better understanding of how individuals' personality and cognitive traits and setting in which word retrieval occurs relate to peoples' ability to produce individual words.

Eligibility criteria:
inclusion criteria: * fluent speakers of english ages 18-30 or ages 65-80

Keywords: mindful breathing anxiety word retrieval
feasibility of comparing two surgical treatment of female urodynamic stress

Conditions: Female Stress Incontinence

Summary: aim: the study aim to assess the feasibly a large prospective multi-centre randomised study for comparing the relatively new "single incision sub-urethral tapes" with the standard surgical treatment of female urodynamic stress incontinence (usi).

single incision tension-free sub-urethral vaginal tapes procedures8 have been recently described in an attempt to avoid the blind passage of the trochars through the groin \& the adductor muscles and consequently reducing the incidence \& severity of postoperative leg pain. the obvious advantages would be shorter hospital stay, early recovery, early resumption of day to day activities \& earlier return to work. a number of small prospective audits and case-series have been presented in international conferences reporting on the safety \& outcomes for these procedures. however all these studies were for preliminary reports for proof of concept and therefore the studies populations were 15-70 women with short term follow-up of 2-3 month9-11.these studies have shown low perioperative complication rates: bladder injury 0-1%, vaginal erosion 1-3% \& one study showing 1.3% pain at 6 weeks follow-up. the patient reported success rates were 77-93% at 2-3 month follow-up9-12. objectives: 1. establish the feasibility of the "single incision sub-urethral tapes" to be done under local anaesthesia. 2. the feasibility of randomisation to the standard surgical treatment tvt-o / tvt. 3. to compare the surgical approach in this relatively new procedure against the standard procedures as regard: peri-operative complication rates, postoperative pain, time to discharge from the hospital, 4. to compare the outcomes as regard: patient-reported cure rates, patient satisfaction, impact on quality of life (qol) and sexual function at 3 month \& 1 -year follow-up. the objective cure rates will be assessed at 3 month follow-up. design: a pilot prospective randomised study within participating urogynaecology units of the "scottish pelvic floor network".

Eligibility criteria:
inclusion criteria: * usi * mixed incontinence symptoms with predominantly bothering stress component (no do on uds). * primary incontinence surgery. * bmi \< 35 * ability to understand the information leaflet and sign an informed consent form in english. * all would have had failed or declined pfmt. exclusion criteria: * mixed incontinence with pre-dominant oab and/or neurological conditions e.g. ms. * detrusor overactivity on urodynamics. * inability to understand english. * un-willing for randomisation. * concomitant surgery. * patient requiring postoperative hospital-stay for medical or social reasons

Keywords: urodynamic urinary incontinence, sub-urethral tape
a home-based rehabilitation in arsacs

Conditions: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Summary: 48 participants (24 women and 24 men) with autosomal recessive spastic ataxia of charlevoix-saguenay (arsacs) will participate in 2 phases : control phase (12-week usual care) and intervention phase (12-week home-based rehabilitation program). the participants will be evaluated at baseline, week 12 (end of control phase) and week 24 (end of intervention phase) to quantify the effects of an individualized home-based rehabilitation program. participants will also participate on a focus group at the end of the program to evaluate the acceptability of the program and the perceived changes.

co-creation phase: preceding the intervention, a co-creation phase involving healthcare professionals (3), patient-partners (2), and arsacs researchers (3) will be conducted to develop the exercises for the rehabilitation program and the evaluation scale to determine the level of difficulty of each exercise assigned to participants. intervention phase: random sampling stratified by gender and level of indoor mobility (unassisted walking, assisted walking, wheelchair) from the neuromuscular clinic's registry of 48 participants (24 women and 24 men) will be conducted. * control phase: all participants will be asked to maintain their usual activities for 12 weeks. * intervention phase: all participants recruited to the project will complete the home-based rehabilitation program assigned to them for 12 weeks, unsupervised, 20 minutes 3 times a week. follow-up calls by a physiotherapist will be conducted at weeks 2, 4, 6, 8, 10 and 12.

Eligibility criteria:
inclusion criteria: * arsacs diagnosis must be confirmed by genetic analysis; * women and men, aged between 18 and 50 years old; * be able to perform the sit-to-stand transfer; * consent of the neurologist must be given to participate in this study; * must reside in the saguenay-lac-st-jean region; * subjects must be able to give their consent freely and voluntarily. exclusion criteria: * patients who already meet physical activity (pa) recommendations (150 min of moderate to high intensity pa/week) or already participate in a rehabilitation program are excluded; * remain in a care facility; * do not speak english or french; * have another diagnosis causing physical limitations; * are pregnant.

Keywords: arsacs
weekly vitamin d in pediatric ibd

Conditions: Inflammatory Bowel Diseases; Skin Pigmentation

Summary: the purpose of this study is to determine whether weekly dosing of oral vitamin d3 is effective in correcting low vitamin d levels in children and adolescents with inflammatory bowel disease (also known as crohn's disease and ulcerative colitis).

the role of vitamin d in skeletal health is well established. more recently, vitamin d has been implicated in multiple other disease states and is currently a topic of much discussion in the pediatric and adult medical literature. individuals with gastrointestinal or hepatobiliary diseases that limit the absorption of dietary vitamin d and those individuals with limited sunlight exposure or darker skin color are at risk for suboptimal vitamin d status. recent joint guidelines from the north american and european societies of pediatric gastroenterology, hepatology and nutrition (naspghan and espghan, respectively) have recommended routine surveillance and treatment for vitamin d insufficiency/deficiency in children affected by inflammatory bowel diseases (ibd), namely crohn's disease (cd) and ulcerative colitis (uc). current recommendations are for prolonged daily dosing of oral vitamin d, but studies in children with other chronic diseases have demonstrated the benefit of improved compliance with less frequent, higher doses of vitamin d. the primary goal of this pilot study is to establish whether weekly dosing of vitamin d can correct suboptimal vitamin d status in children with inflammatory bowel disease. a secondary goal is to evaluate whether pediatric ibd patients with darker skin respond differently to vitamin d therapy than do their lighter-skinned counterparts.

Eligibility criteria:
inclusion criteria: 1. established diagnosis of inflammatory bowel disease made by a pediatric gastroenterologist and confirmed by histopathology 2. serum 25-oh vitamin d level \<30 ng/ml at time of enrollment. 3. age 8-21 years 4. weight \> 20 kg 5. parent, guardian, or subject (where applicable) able to give consent/assent exclusion criteria: 1. inability to ingest oral vitamin d3 capsules 2. presence of known hepatobiliary disease 3. presence of known kidney disease or history of renal stones 4. use of systemic steroids within 60 days prior to enrollment.

Keywords: inflammatory bowel diseases vitamin d cholecalciferol skin pigmentation
safety and efficacy of selonsertib in adults with nonalcoholic steatohepatitis (nash) and bridging (f3) fibrosis

Conditions: Nonalcoholic Steatohepatitis

Summary: the primary objective of this study is to evaluate whether selonsertib (sel; gs-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with nash and bridging (f3) fibrosis.


Eligibility criteria:
key inclusion criteria: * liver biopsy consistent with nash and bridging (f3 fibrosis) according to the nash clinical research network (crn) classification in the opinion of the central reader * has the following laboratory parameters at the screening visit: * alanine aminotransferase (alt) ≤ 8 x upper limit of normal (uln) * creatinine clearance (clcr) ≥ 30 milliliter/minute (ml/min), as calculated by the cockcroft-gault equation * hemoglobin a1c (hba1c) ≤ 9.5% (or serum fructosamine ≤ 381 μmol if hba1c is unable to be resulted) * total bilirubin ≤ 1.3 x uln (unless an alternate etiology such as gilbert's syndrome or hemolytic anemia is present) key exclusion criteria: * prior history of decompensated liver disease including clinical ascites, hepatic encephalopathy (he), or variceal bleeding * child-pugh (cp) score \> 6, as determined at screening, unless due to therapeutic anti-coagulation * model for end-stage liver disease (meld) score \> 12, as determined at screening, unless due to therapeutic anti-coagulation * other causes of liver disease including, but not limited to, alcoholic liver disease, hepatitis b, hepatitis c, autoimmune disorders, drug-induced hepatotoxicity, wilson disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history and/ or centralized review of liver histology. * history of liver transplantation * current or history of hepatocellular carcinoma (hcc) note: other protocol defined inclusion/exclusion criteria may apply.
safety study of plx-pad cells to treat pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this clinical study is to assess the safety of plx-pad to treat pulmonary arterial hypertension (pah). plx-pad is a cell-based product made of allogeneic mesenchymal-like adherent stromal cells (ascs), derived from human full-term placentas following an elective caesarean section. this year-long study will evaluate the safety of three different dose levels of plx-pad, each given as a single intravenous infusion. this study will also evaluate effects that plx-pad may have on pah, such as changes in the ability to exercise and on other tests used to measure the disease severity.


Eligibility criteria:
summary of inclusion and exclusion criteria. eligible subjects: * are between 18 and 75 years of age * have a minimum weight of 45 kg * have a diagnosis of idiopathic or heritable pah, pah associated with connective tissue disease (ctd), pah associated with repaired congenital systemic-to-pulmonary cardiac shunt (at least one year since repair), or pah associated with appetite suppressant/drug or toxin use confirmed by rhc * have a current who functional class ii or iii designation * have been stabilized, without dose changes for at least 30 days prior to the screening visit on at least two approved pah medications (e.g., pde-5 inhibitor, era, prostanoid \[as inhalation or infusion\]); or iv prostanoid monotherapy. subjects on an iv prostanoid must have been receiving therapy for at least three months prior to the screening visit. * have a 6mwd equal to or greater than 200 meters (m) at the screening and baseline visits. subjects must not: * have any evidence of pulmonary thrombus, significant coronary artery disease (cad), left ventricular dysfunction, or a restrictive or congestive cardiomyopathy * have a history of malignancies within the past 5 years,with the exception of individuals with localized, non-metastatic basal cell carcinoma of the skin, in situ carcinoma of the cervix, or prostate cancer who are not currently or expected to undergo radiation therapy, chemotherapy and/or surgical intervention, or to initiate hormonal treatment during the study * be listed for transplantation * be pregnant or nursing

Keywords: cell therapy pulmonary arterial hypertension
study of women who have aids

Conditions: HIV Infections

Summary: to study the effect of pregnancy, age, drug use, and coinfections on hiv progression rate. to document the prevalence, incidence, characteristics, and course of hiv infection and anogenital intraepithelial neoplasia among hiv-positive and hiv-negative women. to study the effect of hiv disease on gynecologic health including infections and reproductive function.


Eligibility criteria:
metabolism of antituberculosis drugs in hiv-infected persons with tuberculosis

Conditions: HIV Infections; Tuberculosis

Summary: the purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of hiv-positive patients with tuberculosis. this study also evaluates how these drugs are absorbed and metabolized in the body.

patients receive up to 8 weeks of two or more anti-tuberculosis drugs, of which at least two are isoniazid, rifampin, pyrazinamide, or ethambutol. blood specimens are collected at 2, 6, and 10 hours after administration of study medication, once between days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen (twice weekly or three times weekly).

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive and have tuberculosis. * are 13 years of age or older. * have written, informed consent of parent or guardian if you are under 18 years of age. * agree to practice abstinence or use barrier methods of birth control during the study. exclusion criteria you will not be eligible for this study if you: * have any other disorder or condition which might cause study treatment to be undesirable. * are pregnant.

Keywords: tuberculosis isoniazid pyrazinamide pyridoxine rifampin aids-related opportunistic infections drug therapy, combination ethambutol acquired immunodeficiency syndrome antitubercular agents
epidemiological study of inflammatory myopathies in a french region

Conditions: Polymyositis

Summary: knowledge of the descriptive epidemiology of mis is very limited. the main objective of this study is to determine the prevalence of inflammatory myopathies in alsace at the 1st january 2012 with "capture-recapture" design using several independent sources of case identification.

inflammatory myopathies (mis) are a group of muscle diseases with a significant heterogeneity, clinical, immunological and prognosis. the old classifications, still currently used, highlight this heterogeneity. therefore troyanov and coll. and hoogendijk and coll. have each recently proposed a classification based on clinical and serological - and immuno- histological examination. the pathogenesis and prognosis of mis is very different depending on the entity in question. knowledge of the descriptive epidemiology of mis is very limited. in fact no epidemiological work using criteria consensual classification is actually started. we propose an epidemiological study of mis. the main objective of the study is to determine the prevalence of mis in alsace at 1stjanuary 2012 by means of a "capture- recapture" study using several independent sources of case identification. the secondary objectives of the study are: * estimating the geographical distribution of the disease in the alsace region and / or auvergne * demographic description of patients : age, sex, residence , occupation * description of the disease: patient age at diagnosis, disease classification , main clinical manifestations and complications * identification of paraneoplastic forms will be for the alsace region by crossing with alsatian cancer registries. these records will be interviewed to identify cases of mis associated with cancers.

Eligibility criteria:
inclusion criteria: * all patient reported suffering from inflammatory myopathy * meeting the hoogendijk, troyanov and griggs classification criteria * alive at 1st january 2012- domiciled in alsace (bas-rhin or haut-rhin counties of france) exclusion criteria: * all patient reported with a different or incomplete diagnosis of inflammatory myopathy (not meeting the hoogendijk, troyanov and griggs criteria) * all patient dead and/or non-domiciled in alsace at 1st january 2012
internet cbt for trichotillomania and skin picking disorder

Conditions: Trichotillomania; Excoriation (Skin-Picking) Disorder

Summary: the primary aim of the study is to test the feasibility, safety and efficacy of a manual based, internet-delivered, behavior therapy (i-bt) for trichotillomania and skin picking disorder.


Eligibility criteria:
inclusion criteria: * primary diagnosis of trichotillomania and/or skin picking disorder according to dsm-5 * living in sweden with a swedish personal identification number * able to participate in study assessment in swedish and understand swedish text * have regular access to a computer with internet access and skills to use internet * signed informed consent * outpatient exclusion criteria: * psychotropic medication changes that can affect symptoms of trichotillomania or skin picking disorder within 2 months prior to treatment * other ongoing psychological treatments that could affect symptoms of trichotillomania or skin picking disorder * completed cbt for trichotillomania or skin picking disorder within the last 24 months * ongoing substance dependence or misuse * lifetime bipolar disorder or psychosis * suicidal ideation (a score of 5 points or higher on item 9 on the self-reported montgomery-åsberg depression rating scale * psychiatric comorbidity that could severely jeopardize treatment participation
epidemiology of thrombotic thrombocytopenia syndrome in integrated health-care database in england

Conditions: COVID-19

Summary: background/rationale: a rare syndrome of thrombosis associated with low platelets has been reported in a few cases of recent exposure to covid-19 vaccine. medicines \& healthcare products regulatory agency (mhra) had requested for all cases of thrombosis or thrombocytopenia occurring within 28 days of coronavirus vaccine to be reported via the online yellow card system. this syndrome seems to be affecting patients of all ages and both genders; at present there is no clear signal of risk factors. up to and including 14 april 2021, the mhra had received 168 united kingdom (uk) reports of thrombo-embolic events with concurrent low levels of platelets following the use of the covid-19 vaccine astrazeneca. the united kingdom (uk) is uniquely placed to study this area because of its registration-based primary care system, and a unique identifier number links primary care to secondary care data. additionally, vaccination is well advanced, maximising population wide vaccine exposure. objectives and hypotheses: estimate event rates and describe characteristics of patients with a record for thrombotic thrombocytopenia syndrome, thromboembolism or thrombocytopenia, in the general population of england. methods: study design: secondary data analysis using a cohort design. data source(s): this is a retrospective cohort study using linked secondary databases in england accessed through the nhs digital trusted research environment (tre). the primary care data will be linked with vaccination, primary care data, hospitalization, covid-19 test results, mortality data at the national level for capture of key study variables. this integrated digital health system will also include other linkages such as the oxford-royal college of general practitioners sentinel network; orchid. study population: all patients, with our population of interest in england who are present in the integrated health records of nhs digital tre and/or the oxford royal college of general practitioners clinical informatics digital hub (orchid) database at the start of each study period. variables: demographic, socioeconomic, clinical descriptors and risk factors for thrombosis and/or thrombocytopenia; covid-19 vaccines. statistical analysis: the event rates with 95% cis will be calculated by dividing the number of events with person-time at risk per 100,000 person-years. further, event count and event rates will be evaluated in a relationship with covid-19 vaccination date.


Eligibility criteria:
inclusion criteria: * all patients, with a primary focus from age 16 years old and older, in england who are present in the integrated database at the start of each study period. exclusion criteria: * less than 12 months of prior history at start of each respective study period.
swallowing, speech and quality of life of patients with carcinoma of the oropharynx

Conditions: Squamous Cell Carcinoma of the Oropharynx

Summary: the curative treatment and organ preservation in advanced squamous cell carcinoma of the oropharynx is multimodal. it involves induction chemotherapy and depending on the response radio-chemotherapy or surgery. the combination of these methods has important functional consequences. the aim of this prospective pilot study is to describe swallowing, speech, but also patients' quality of life before and after therapeutic management (existing studies measuring these functions after treatment but not before).

this study will not change the patient's treatment. this will just be an evaluation, before any treatment, his ability to swallow, speak then, as in normal practice, after 3, 6 and 12 months after treatment.

Eligibility criteria:
inclusion criteria: * patient with stage t3 or t4 squamous cell carcinoma of the oropharynx previously untreated. * performance status 0 or 1 * tumor histology proving squamous cell carcinoma exclusion criteria: * visceral metastases at initial assessment * contraindication to surgery and / or chemotherapy such as: * a history of other cancer (except basal cell carcinoma skin or cervical cancer in situ) * 2nd associated cancer

Keywords: squamous cell carcinoma of the oropharynx swallowing, speech quality of life